fbpx
QQQ
+ 5.10
331.41
+ 1.52%
DIA
+ 2.91
334.63
+ 0.86%
SPY
+ 4.32
407.26
+ 1.05%
TLT
+ 2.31
135.73
+ 1.67%
GLD
+ 2.66
160.03
+ 1.64%

Coherus Biosciences Falls 30% After FDA Response Letter

by
June 12, 2017 10:32 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Coherus Biosciences Inc (NASDAQ:CHRS) shares are trading lower by $6.50 (30 percent) at $14.15 percent in Monday's session.

The Street isn't acting favorably to the FDA's Complete Response Letter for its application for its CHS-1701. In the letter, the FDA has requested additional information in which the company has pledged to provide.

After a much lower open, Coherus immediately bottomed at $14.05 and managed a brief rally to $14.98. That low coincides with its early July 2016 low at $14.00. It has been unable to sustain that rally and is drifting back towards the lows for the session.


Related Articles

Stocks Which Set New 52-Week High Yesterday, August 28th

Stocks Which Set New 52-Week High Friday, July 27th

Stocks Which Set New 52-Week High Yesterday, July 24th:

Stocks Which Set New 52-Week High Yesterday: